Tukua

Tukua

Download on the App Store

Tukua episodes

  • Dactilítis
    ¡Gracias por escuchar! En este episodio repaso algunos conceptos relevantes sobre la dactilítis, una manifestación común en espondiloartritis. Les pido amablemente que califiquen este episodio en iTunes, o dejen sus comentarios en esta página. El podcast se encuentra disponible también en Spotify y a través de la aplicación gestora de podcasts de su elección.
    Abajo enlisto referencias útiles, algunas mencionadas en el episodio:
     
    Olivieri, I., Scarano, E., Padula, A., Giasi, V. & Priolo, F. Dactylitis, a term for different digit diseases. Scand. J. Rheumatol. 35, 333–340 (2006).
     
    Gladman, D. D., Ziouzina, O., Thavaneswaran, A. & Chandran, V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J. Rheumatol. 40, 1357–1359 (2013).
     
    Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957–970 (2017).
     
    Rothschild, B. M., Pingitore, C. & Eaton, M. Dactylitis: implications for clinical practice. Semin. Arthritis Rheum. 28, 41–47 (1998).
     
    Taylor, W. J. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665–2673 (2006).
     
    Rudwaleit, M. et al. The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25–31 (2011).
     
    Brockbank, J. E., Stein, M., Schentag, C. T. & Gladman, D. D. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann. Rheum. Dis. 64, 188–190 (2005).
     
    Kavanaugh, A., Helliwell, P. & Ritchlin, C. T. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol. Ther. 3, 91–102 (2016).
     
    Kaeley, G. S., Eder, L., Aydin, S. Z., Gutierrez, M. & Bakewell, C. Dactylitis: a hallmark of psoriatic arthritis. Semin. Arthritis Rheum. 48, 263–273 (2018).
     
    McGonagle, D., Conaghan Philip, G. & Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 42, 1080–1086 (2001).
     
    Tinazzi, I. et al. ‘Deep Koebner’ phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann. Rheum. Dis. 77, 922 (2018).
     
    Pattison, E., Harrison, B. J., Griffiths, C. E., Silman, A. J. & Bruce, I. N. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann. Rheum. Dis. 67, 672–676 (2008).
     
    Ng, J., Tan, A. L. & McGonagle, D. Unifocal psoriatic arthritis development in identical twins following site specific injury: evidence supporting biomechanical triggering events in genetically susceptible hosts. Ann. Rheum. Dis. 74, 948–949 (2015).
     
    Jacques, P. et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437–445 (2014).
     
    Jacques, P. & McGonagle, D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract. Res. Clin. Rheumatol. 28, 703–710 (2014).
     
    Thorarensen, S. M. et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 76, 521–525 (2017).
     
    Wilkins, R. A., Siddle, H. J., Redmond, A. C. & Helliwell, P. S. Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study. Clin. Rheumatol. 35, 2333–2338 (2016).
     
    Tan, A. L. & McGonagle, D. The need for biological outcomes for biological drugs in psoriatic arthritis. J. Rheumatol. 43, 3–6 (2016).
     
    Mumtaz, A. et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann. Rheum. Dis. 70, 272–277 (2011).
     
    Helliwell, P. S. et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann. R
    18 min
  • Tratamiento del Síndrome de Sjögren Primario
    ¡Gracias por escuchar! En este episodio se hablará acerca de las alternativas de tratamiento del síndrome de Sjögren primario, tanto glandular como extraglandular.
    Recuerden que su retroalimentación es bienvenida y les pido amablemente califiquen el podcast en iTunes. Además, Tukua se encuentra disponible en Spotify o a través del gestor de podcasts de su elección.
    A continuación enlisto algunos de los artículos revisados para este episodio:
     
    Vitali, C. et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria 21. proposed by the American-European ConsensusGroup. Ann. Rheum. Dis. 61, 554–558 (2002).
    Shiboski, S. C. et al. American College of 22. Rheumatology classification criteria for Sjögren’ssyndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical 23. Alliance cohort. Arthritis Care Res. (Hoboken) 64, 475–487 (2012).
    Seror, R. et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic 25. disease activity index for primary Sjögren’s syndrome. Ann. Rheum. Dis. 69, 1103–1109 (2010).
    Seror, R. et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s 26. syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum. Dis. 75, 382–389 (2016).
    Seror, R. et al. EULAR Sjögren’s Syndrome Patient 27. Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome. Ann. Rheum. Dis. 70, 968–972 (2011).
    Theander, E. et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the 28. development of malignant lymphoma in primary Sjögren’s syndrome. Ann. Rheum. Dis. 70, 29. 1363–1368 (2011).
    Valim, V. et al. Recommendations for the treatment 33. of Sjögren’s syndrome. Rev. Bras. Reumatol. 55, 446–457 (in Portuguese) (2015).
    Furness, S., Worthington, H. V., Bryan, G., Birchenough, S. & McMillan, R. Interventions for the management of dry mouth: topical therapies. 34. Cochrane Database Syst. Rev. 12, CD008934 (2011).
    Steller, M., Chou, L. & Daniels, T. E. Electrical stimulation of salivary flow in patients with Sjögren’s syndrome. J. Dent. Res. 67, 1334–1337 (1988).
    Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. 159, 174–181 (1999).
    Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960–968 (2010).
    Forstot, S. L. & Foulks, G. N. Management of Dry Eye (Oxford Univ. Press, 2012).
    Toda, I., Shinozaki, N. & Tsubota, K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren’s syndrome. Cornea 15, 120–128 (1996).
    Marsh, P. & Pflugfelder, S. C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 106, 811–816 (1999).
    Barber, L. D., Pflugfelder, S. C., Tauber, J. & Foulks, G. N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112, 1790–1794 (2005).
    Milin, M. et al. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren’s syndrome. Joint Bone Spine http://dx.doi. org/10.1016/j.jbspin.2015.10.005 (2016).
    van Leeuwen, N. et al. Psychological profiles in patients with Sjögren’s syndrome related to fatigue: a cluster analysis. Rheumatology (Oxford) 54, 776–783 (2015).
    Segal, B. et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren’s syndrome. Arthritis Rheum. 59, 1780–1787 (2008).
    Gottenberg, J. E. et al. Effects of hydroxych
    32 min
  • Nuevas Estrategias Terapéuticas en Lupus
    ¡Gracias por escuchar! En este episodio se discuten las nuevas estrategias terapéuticas para el manejo del Lupus Eritematoso Sistémico. Agradezco su retroalimentación y les pido amablemente que califiquen el episodio en iTunes y en Spotify. No olviden dejar sus comentarios y sugerencias en tukua.podbean.com. 
    Abajo enlisto las referencias bibliográficas consultadas en este episodio:
     
    Piga, M. et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis. Res. Ther. 19, 247 (2017).
     
    Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949–956 (2010).
     
    Iaccarino, L. et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J. Autoimmun. 86, 1–8 (2018).
     
    Calixto, O. J., Franco, J. S. & Anaya, J. M. Lupus mimickers. Autoimmun. Rev. 13, 865–872 (2014).
     
    Doria, A. & Briani, C. Lupus: improving long-term prognosis. Lupus 17, (166–170 (2008).
     
    Bizzarro, N. et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.J. Thromb. Haemost. 5, 1158–1164 (2007).
     
    Pengo, V. et al. Efficacy and safety of rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25, 301–306 (2016).
     
    Arnaud, L. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 14, 192–200 (2015).
     
    Ruiz-Irastorza, G. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20, 206–218 (2011).
     
    Moroni, G. et al. Changing patterns in clinical- histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318–1325 (2018).
     
    van Vollenhoven, R. et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann. Rheum. Dis. 76, 554–561 (2017).
     
    Bertsias, G. et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/ ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771–1782 (2012).
     
    Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706–1713 (2015).
     
    Al Sawah, S. et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus. Sci. Med. 2, e000066 (2015).
     
    Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).
     
    Fischer-Betz, R. et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J. Rheumatol. 39, 2111–2117 (2012).
     
    Merrill, J. T. et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus. Sci. Med. 5, e000258 (2018).
     
    Iaccarino, L. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 69, 115–123 (
    27 min
  • Aspectos Éticos de la Investigación Clinica .
    ¡Gracias por escuchar! El episodio 5 difiere de los anteriores al hablar de los aspectos éticos relacionados a la investigación clínica. Este tema es importante ya que los médicos clínicos empleamos evidencia para el tratamiento de nuestros pacientes y frecuentemente desconocemos la manera en la que se conducen los investigadores en relación a la ética de los proyectos que desarrollan.
    No olviden calificar el episodio (y todo el podcast) en iTunes y en Spotify. Su retroalimentación es muy importante.
    A continuación enumero el material mencionado en el episodio:
     
    https://history.nih.gov/research/downloads/nuremberg.pdf
     
    https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
     
    https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html
     
    https://cioms.ch/
     
    https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html
    21 min
  • Tratamiento del dolor en osteoartritis inflamatoria
    ¡Gracias por escuchar! En este episodio hablaré del papel que juega la inflamación en la generación de dolor en pacientes con osteoartritis. La OA tiene una morbilidad asociada sustancial y constituye un creciente problema de salud pública derivado en gran medida del envejecimiento poblacional. Los síntomas de la OA pueden ser funcionales pero se manifiestan principalmente como dolor y el manejo de la enfermedad se centra principalmente en su control.
    Agradezco que escuchen este podcast y les recuerdo que se encuentra disponible en el catálogo de iTunes, en Google Play (siendo accesible a través del gestor de podcasts de su dispositivo móvil), así como en Spotify. Agradezco también su retroalimentación en estas plataformas y les pido amablemente que califiquen el podcast ya que esto es importante para su continuado desarrollo.
    A continuación se enlistan las referencias mencionadas en este episodio:
     
    Grace, P. M., Hutchinson, M. R., Maier, S. F. & Watkins, L. R. Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 14, 217–231(2014).
    Owens, C. & Conaghan, P. G. Improving joint pain and function in osteoarthritis. Practitioner 260, 17–20 (2016).
    O’Neil, C. K., Hanlon, J. T. & Marcum, Z. A. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am. J. Geriatr. Pharmacother. 10, 331–342 (2012).
    Wang, Y., Teichtahl, A. J. & Cicuttini, F. M. Osteoarthritis year in review 2015: imaging. Osteoarthritis Cartilage 24, 49–57 (2016).
    Haringman, J. J., Smeets, T. J., Reinders-Blankert, P. & Tak, P. P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. 65, 294–300 (2006).
    de Lange-Brokaar, B. J. et al. Degree of synovitis on MRI by comprehensive whole knee semi-quantitative scoring method correlates with histologic and macroscopic features of synovial tissue inflammation in knee osteoarthritis. Osteoarthritis Cartilage 22, 1606–1613 (2014).
    Cook, A. D., Christensen, A. D., Tewari, D., McMahon, S. B. & Hamilton, J. A. Immune cytokines and their receptors in inflammatory pain. Trends Immunol. 39, 240–255 (2018).
    Malfait, A. M. & Schnitzer, T. J. Towards a mechanism-based approach to pain management in osteoarthritis. Nat. Rev. Rheumatol. 9, 654–664 (2013).
    Bellamy, N. et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst. Rev. 2, CD005328 (2006).
    McAlindon, T. E. et al. Effect of intra-articular triamcinolone versus saline on knee cartilage volume and pain in patients with knee osteoarthritis:a randomized clinical trial. JAMA 317, 1967–1975 (2017).
    Aitken, D. et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis — the HUMOR trial. Osteoarthritis Cartilage 26, 880–887 (2018).
    Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).
    Wang, S. X. et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1alpha/beta dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis Cartilage 25, 1952–1961 (2017).
    Eitner, A., Hofmann, G. O. & Schaible, H. G. Mechanisms of osteoarthritic pain. Studies in humans and experimental models. Front. Mol. Neurosci. 10, 349 (2017).
    Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. Cell 139, 267–284 (2009).
    Ji, R. R., Xu, Z. Z. & Gao, Y. J. Emerging targets in neuroinflammation-driven chronic pain. Nat. Rev. Drug Discov. 13, 533–548 (2014).
    McMahon, S. B., La Russa, F. & Bennett, D. L. Crosstalk between the nociceptive and immune systems in host defence and disease. Nat. Rev. Neurosci. 16, 3
    15 min
  • Metotrexato
    ¡Gracias por Escuchar! En esta ocasión hablaré acerca del mecanismo de acción del fármaco mas importante y de mayor uso para el tratamiento de varias enfermedades, principalmente Artritis Reumatoide, el Metotrexato. Para este episodio consulté varias fuentes, tratando de presentar evidencia en humanos sobre su interesante funcionamiento. 
    Recuerden que su retroalimentación es bienvenida y muy importante. Les pido amablemente dejen sus calificaciones y comentarios sobre el podcast en iTunes. Próximamente el podcast estará disponible en Google Play y se encuentra disponible en Spotify, pudiendo también acceder a el a través de su gestor de podcasts favorito.
    A continuación se encuentra una lista de las referencias consultadas para este episodio.
    Lopez-Olivo, M. A. et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 6, CD000957 (2014).
    Kavanaugh, A. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72, 64–71 (2013).
    Detert, J. et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann. Rheum. Dis. 72, 844–850 (2013).
    Horslev-Petersen, K. et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra- articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo- controlled trial. Ann. Rheum. Dis. 73, 654–661 (2014).
    O’Dell, J. R. et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 65, 1985–1994 (2013).
    Bathon, J. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586–1593 (2000).
    Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).
    Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381–3390 (2005).
    Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis. Rheum. 54, 26–37 (2006).
    Soubrier, M. et al. Evaluation of two strategies (initial methotrexate monotherapy versus its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48, 1429–1434 (2009).
    Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39–46 (2011).
    de Jong, P. H. et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. 72, 72–78 (2013).
    Emery, P. et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-bli
    17 min
  • Artritis Reumatoide, Artritis Psoriásica y Enfermedad Metabólica.
    ¡Gracias por escuchar!
     
    Ahora ya se puede acceder a Tukua a través de iTunes.
    Agradezco sus comentarios y retroalimentación y les ruego se suscriban al podcast.
     
    A continuación se enlistan los artículos mencionados en el episodio 2.
     
    Karpouzas, G. A. et al. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann. Rheum. Dis. 73, 1797–1804 (2014).
     
    Maki-Petaja, K. M. et al. Anti-tumor necrosis factor therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 126, 2473–2480 (2012).
     
    The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009).
     
    van Sijl, A. M. et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta- analysis. Semin. Arthritis Rheum. 41, 393–400 (2011).
     
    Queiro, R. et al. Prevalence and type II diabetes- associated factors in psoriatic arthritis. Clin. Rheumatol. 37, 1059–1064 (2018).
     
    Dubreuil, M. et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology 53, 346–352 (2014).
     
    Siebert, S. et al. Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. RMD Open 2, e000267 (2016).
     
    Coxib and Traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769–779 (2013).
     
    Roubille, C. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti- inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta- analysis. Ann. Rheum. Dis. 74, 480–489, (2015)
     
    Zhang, J. et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1813–1818 (2016)
    18 min
  • Riesgo cardiovascular en Artritis Reumatoide y Artritis Psoriásica.
    Gracias por escuchar. Estas son los artículos a los que se hace referencia en este episodio del podcast:
    Ogdie, A. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 74, 326–332 (2014).
    Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoidarthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).
    Schieir, O., Tosevski, C., Glazier, R. H., Hogg-Johnson, S.& Badley, E. M. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann. Rheum. Dis. 76, 1396–1404 (2017). 21.
    D’Agostino, R. B. et al. General cardiovascular risk profile for use in primary care. Circulation 117, 743–753 (2008).
    Arts, E. E. A. et al. Performance of four current risk 23. algorithms in predicting cardiovascular events inpatients with early rheumatoid arthritis. Ann. Rheum.Dis. 74, 668–674 (2015). 24.
    Crowson, C. S., Matteson, E. L., Roger, V. L., Therneau, T. M. & Gabriel, S. E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am. J. Cardiol. 110, 420–424 (2012). 25.
    Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms ofinflammatory joint disorders: 2015/2016 update. 26. Ann. Rheum. Dis. 76, 17–28 (2017).
    Gómez-Vaquero, C. et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis 27. Res. Ther. 15, R91 (2013).
    Ahlehoff, O. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J. Intern. Med. 270, 147–157 (2011).
    Polachek, A., Touma, Z., Anderson, M. & Eder, L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 69, 67–74 (2017).
    Gulati, A. M. et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann. Rheum. Dis. 75, 819–824 (2016).
    Eder, L., Wu, Y., Chandran, V., Cook, R. & Gladman, D. D. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann. Rheum. Dis. 75, 1680–1686 (2016).
    Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study.J. Rheumatol. 45, 378–384 (2018).
    Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).
    Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
    Sever, P. S. et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo- Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J. Am. Coll. Cardiol. 62, 717–729 (2013).
    Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
    Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
    Szentpetery, A. et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 70, 396–407 (2018).
    Min, J. K. et al. Relationship of coronary artery plaque composition to coronary artery stenosis severity: results from the prospective multicenter ACCURACY trial. Atherosclerosis 219, 573–578 (2011).
    18 min
  • ¡Bienvenidos a Tukua!
    Tukua es un proyecto dirigido a los reumatólogos hispanoparlantes y a profesionales de la medicina afines a esta especialidad y que tiene tres objetivos:
    1. Difundir evidencia científica del campo de la reumatología que resulte práctica, que se pueda emplear en nuestra práctica diaria y que conduzca a la mejor atención de nuestros pacientes.
    2. Fomentar la discusión de esta evidencia con el público que (espero) escuche y me retroalimente sobre este podcast, de manera que se genere y enriquezca la conversación profesional entre nosotros.
    3. Contribuír a fortalecer la reumatología a través de este medio de comunicación, en español, deseando llegue a todos los profesionales que se dedican al cuidado de los pacientes con enfermedades reumáticas.
    Tukua es un vocablo otomí, una etnia del centro de México, que significa Reuma; consideré que la palabra tukua no solo le brindaba cierto aire regional a este proyecto y que además era un nombre original y adecuado.
    2 min

About Tukua

From the publisher's feed

Evidencia para profesionales de la medicina y áreas afines interesados en Reumatología